Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing

  • Nemtsova M.
  • Kalinkin A.
  • Kuznetsova E.
  • Bure I.
  • Alekseeva E.
  • Bykov I.
  • Khorobrykh T.
  • Mikhaylenko D.
  • Tanas A.
  • Kutsev S.
  • Zaletaev D.
  • Strelnikov V.
Дата публикации:01.12.2020
Журнал: Scientific Reports
БД: Scopus
Ссылка: Scopus


© 2020, The Author(s). Somatic mutation profiling in gastric cancer (GC) enables main driver mutations to be identified and their clinical and prognostic value to be evaluated. We investigated 77 tumour samples of GC by next-generation sequencing (NGS) with the Ion AmpliSeq Hotspot Panel v2 and a custom panel covering six hereditary gastric cancer predisposition genes (BMPR1A, SMAD4, CDH1, TP53, STK11 and PTEN). Overall, 47 somatic mutations in 14 genes were detected; 22 of these mutations were novel. Mutations were detected most frequently in the CDH1 (13/47) and TP53 (12/47) genes. As expected, somatic CDH1 mutations were positively correlated with distant metastases (p = 0.019) and tumours with signet ring cells (p = 0.043). These findings confirm the association of the CDH1 mutations with diffuse GC type. TP53 mutations were found to be significantly associated with a decrease in overall survival in patients with Lauren diffuse-type tumours (p = 0.0085), T3-T4 tumours (p = 0.037), and stage III-IV tumours (p = 0.013). Our results confirm that the detection of mutations in the main driver genes may have a significant prognostic value for GC patients and provide an independent GC-related set of clinical and molecular genetic data.

Вернуться назад
про COVID-19